2010
DOI: 10.1002/jmv.21921
|View full text |Cite
|
Sign up to set email alerts
|

Low prevalence of transmitted drug resistance among newly diagnosed HIV‐1 patients in Latvia

Abstract: Transmitted drug resistance (TDR) is a concern because it may reduce the efficacy of antiretroviral treatment. Plasma samples of 119 HIV-1-infected patients who were newly diagnosed at the Infectology Center of Latvia in 2005 and 2006 were analyzed by an in-house genotypic resistance assay to determine the prevalence of TDR in Latvia. TDR was identified using the WHO 2009 list of mutations for surveillance of TDR as implemented in the Stanford Calibrated Population Resistance tool. Neighbor-joining phylogeneti… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
5
0

Year Published

2011
2011
2020
2020

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 10 publications
(5 citation statements)
references
References 41 publications
0
5
0
Order By: Relevance
“…Importantly, the use of cART in Eastern Europe has increased considerably in the 2000s, mainly within the format of potent drug regimens rather than suboptimal mono-or dual therapy (12). The reported data of TDR from FSU countries vary but are generally below 10% [0% in Lithuania (13), 2.1% in Ukraine (10), 3-7% in Latvia (14,15), 0-13% in Russia (depending on the study) (16)].…”
Section: Introductionmentioning
confidence: 99%
“…Importantly, the use of cART in Eastern Europe has increased considerably in the 2000s, mainly within the format of potent drug regimens rather than suboptimal mono-or dual therapy (12). The reported data of TDR from FSU countries vary but are generally below 10% [0% in Lithuania (13), 2.1% in Ukraine (10), 3-7% in Latvia (14,15), 0-13% in Russia (depending on the study) (16)].…”
Section: Introductionmentioning
confidence: 99%
“…However, an increasing trend was found for NNRTI resistance in the Americas/Caribbean, Europe and upper-income Asia. These estimates were modeled by sample year or by year due to antiretroviral treatment scale-up in different regions [ 5 , 6 , 7 , 8 ], suggesting that the incidence of resistance is unknown. Estimates of primary resistance have been based mostly on the proportions of newly diagnosed individuals carrying resistance strains [ 5 , 6 , 9 ], and in a few studies on proportions of resistant strains among newly or acutely infected subjects [ 10 , 11 , 12 , 13 , 14 , 15 ].…”
Section: Introductionmentioning
confidence: 99%
“…In the past, the transmission of drug-resistant viruses, which can sometimes persist even without the selective pressure of HAART, was becoming increasingly frequent (9,20). Nowadays, several studies show a decline in the transmission of drug-resistant variants in the western world to approximately 10% (2,14), whereas other studies still report stable transmission rates for certain resistance-associated mutations (RAMs) (5,45). The key to an effective treatment regimen relies on both the genetic barrier to resistance to a specific drug and on the ability of antiviral drugs to decrease viral load.…”
mentioning
confidence: 99%